{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T22:27:41Z","timestamp":1793485661877,"version":"4.5.0"},"reference-count":55,"publisher":"The Endocrine Society","issue":"7","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are increasingly prescribed to older adults with type 2 diabetes for their metabolic and cardiovascular benefits, but their effects on bone health in this high-risk population are not well established.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The aim of this study was to assess the risk of fragility fractures associated with GLP-1RA therapy compared to sodium-glucose cotransporter-2 inhibitors or dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a population-based retrospective new-user cohort study using the nationwide Clalit Health Services database. Participants included people with type 2 diabetes aged 65 years or older who initiated GLP-1RA therapy or comparator drugs during 2018 to 2022. The primary outcome was first fragility fracture. Follow-up continued until fracture occurrence, death, or March 31, 2024. An intention-to-treat approach was used. Baseline characteristics were balanced using inverse probability of treatment weighting based on propensity scores. Hazard ratios (HRs) were estimated using multivariate survival analysis accounting for the competing risk of death.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study included 46 177 participants: 11 257 GLP-1RA users and 34 920 comparator drug users. During a median follow-up of 34.7 months, 4086 (8.8%) individuals experienced a fragility fracture and 4595 (10.0%) died. In the propensity score\u2013weighted model adjusted for baseline characteristics and competing risk of death, new users of GLP-1RAs had an 11% increased fracture risk compared to the comparator group (HR 1.11; 95% CI, 1.01-1.21).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Initiating GLP-1RA therapy was associated with a modestly increased risk of fragility fractures in older adults with type 2 diabetes. These findings may inform clinical decisions by balancing clinical benefits against potential skeletal risks in this vulnerable population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgag056","type":"journal-article","created":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T12:34:20Z","timestamp":1770554060000},"page":"1949-1958","source":"Crossref","is-referenced-by-count":14,"title":["GLP-1 receptor agonists and the risk of fragility fractures in older adults with type 2 diabetes"],"prefix":"10.1210","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8149-8514","authenticated-orcid":false,"given":"Michal","family":"Kasher Meron","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Meir Medical Center , Kfar Saba 4428164 ,","place":["Israel"]},{"name":"School of Medicine, Gray Faculty of Medical and Health Sciences, Tel Aviv University , Tel Aviv 6997801 ,","place":["Israel"]},{"name":"The Gertner Institute for Epidemiology and Health Policy Research, Sheba Medical Center , Ramat Gan 5266202 ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2122-5116","authenticated-orcid":false,"given":"Tzipi","family":"Hornik-Lurie","sequence":"additional","affiliation":[{"name":"Research Department, Meir Medical Center , Kfar Saba 4428164 ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2829-3645","authenticated-orcid":false,"given":"Gilad","family":"Twig","sequence":"additional","affiliation":[{"name":"The Gertner Institute for Epidemiology and Health Policy Research, Sheba Medical Center , Ramat Gan 5266202 ,","place":["Israel"]},{"name":"The Institute of Endocrinology Diabetes and Metabolism, Sheba Medical Center , Ramat Gan 5266202 ,","place":["Israel"]},{"name":"Department of Preventive Medicine and Epidemiology, School of Public Health, Gray Faculty of Medical and Health Sciences, Tel Aviv University , Tel Aviv 6997801 ,","place":["Israel"]},{"name":"Incumbent of the Hella Gertner Chair for Research in Hypertension, Gray Faculty of Medical and Health Sciences, Tel Aviv University , Tel Aviv 6997801 ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6029-7593","authenticated-orcid":false,"given":"Pnina","family":"Rotman-Pikielny","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Meir Medical Center , Kfar Saba 4428164 ,","place":["Israel"]},{"name":"School of Medicine, Gray Faculty of Medical and Health Sciences, Tel Aviv University , Tel Aviv 6997801 ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"issue":"8","key":"2026061619574906800_dgag056-B1","doi-asserted-by":"crossref","first-page":"e242026","DOI":"10.1001\/jamahealthforum.2024.2026","article-title":"Prescription fills for semaglutide products by payment method","volume":"5","author":"Scannell","year":"2024","journal-title":"JAMA Health Forum"},{"key":"2026061619574906800_dgag056-B2","doi-asserted-by":"crossref","first-page":"110742","DOI":"10.1016\/j.diabres.2023.110742","article-title":"Prescribing trends of glucose-lowering drugs in older adults from 2010 to 2021: a population-based study of Northern Italy","volume":"202","author":"Foresta","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"issue":"8","key":"2026061619574906800_dgag056-B3","doi-asserted-by":"crossref","first-page":"e228","DOI":"10.37765\/ajmc.2025.89778","article-title":"Trends in glucagon-like peptide 1 receptor agonist prescribing patterns","volume":"31","author":"Ukhanova","year":"2025","journal-title":"Am J Manag Care"},{"issue":"8","key":"2026061619574906800_dgag056-B4","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41573-025-01183-8","article-title":"GLP-1-based therapies for diabetes, obesity and beyond","volume":"24","author":"Drucker","year":"2025","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"2026061619574906800_dgag056-B5","doi-asserted-by":"crossref","first-page":"835","DOI":"10.2337\/dc06-1851","article-title":"The risk of hip fractures in older individuals with diabetes: a population-based study","volume":"30","author":"Lipscombe","year":"2007","journal-title":"Diabetes care"},{"issue":"2","key":"2026061619574906800_dgag056-B6","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s11914-024-00867-1","article-title":"Diagnosing osteoporosis in diabetes-a systematic review on BMD and fractures","volume":"22","author":"Brandt","year":"2024","journal-title":"Curr Osteoporos Rep"},{"issue":"1","key":"2026061619574906800_dgag056-B7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12902-022-01260-8","article-title":"Prevalence of osteoporosis in patients with diabetes mellitus: a systematic review and meta-analysis of observational studies","volume":"23","author":"Liu","year":"2023","journal-title":"BMC Endocr Disord"},{"issue":"2","key":"2026061619574906800_dgag056-B8","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00125-023-06054-8","article-title":"Hyperglycaemia, diabetes and risk of fragility fractures: observational and Mendelian randomisation studies","volume":"67","author":"Emanuelsson","year":"2024","journal-title":"Diabetologia"},{"issue":"7","key":"2026061619574906800_dgag056-B9","doi-asserted-by":"crossref","first-page":"e3168","DOI":"10.1002\/dmrr.3168","article-title":"Glucagon-like peptide-1 receptor agonists and risk of bone fracture in patients with type 2 diabetes: a meta-analysis of randomized controlled trials","volume":"35","author":"Cheng","year":"2019","journal-title":"Diabetes Metab Res Rev"},{"key":"2026061619574906800_dgag056-B10","doi-asserted-by":"crossref","first-page":"735824","DOI":"10.3389\/fendo.2021.735824","article-title":"Effects of anti-diabetic drugs on fracture risk: a systematic review and network meta-analysis","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"2026061619574906800_dgag056-B11","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026061619574906800_dgag056-B12","doi-asserted-by":"crossref","first-page":"102624","DOI":"10.1016\/j.eclinm.2024.102624","article-title":"Once-weekly semaglutide versus placebo in adults with increased fracture risk: a randomised, double-blinded, two-centre, phase 2 trial","volume":"72","author":"Hansen","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"5","key":"2026061619574906800_dgag056-B13","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.diabet.2019.01.010","article-title":"Risk of bone fracture associated with sodium-glucose cotransporter-2 inhibitor treatment: a meta-analysis of randomized controlled trials","volume":"45","author":"Cheng","year":"2019","journal-title":"Diabetes Metab"},{"key":"2026061619574906800_dgag056-B14","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.diabres.2018.10.019","article-title":"Sodium-glucose cotransporter 2 inhibitors and fracture risk in patients with type 2 diabetes mellitus: a systematic literature review and Bayesian network meta-analysis of randomized controlled trials","volume":"146","author":"Azharuddin","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"2026061619574906800_dgag056-B15","doi-asserted-by":"crossref","first-page":"29104","DOI":"10.1038\/srep29104","article-title":"Dipeptidyl peptidase-4 inhibitors and fracture risk: an updated meta-analysis of randomized clinical trials","volume":"6","author":"Fu","year":"2016","journal-title":"Sci Rep"},{"key":"2026061619574906800_dgag056-B16","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.diabres.2016.04.029","article-title":"DPP-4 inhibitor therapy and bone fractures in people with type 2 diabetes\u2014a systematic review and meta-analysis","volume":"116","author":"Mamza","year":"2016","journal-title":"Diabetes Res Clin Pract"},{"issue":"12","key":"2026061619574906800_dgag056-B17","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1007\/s00198-023-06908-2","article-title":"Effect of SGLT2 inhibitors on fractures, BMD, and bone metabolism markers in patients with type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"34","author":"Wang","year":"2023","journal-title":"Osteoporos Int"},{"issue":"Suppl 1","key":"2026061619574906800_dgag056-B18","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.2337\/dc22-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2022","volume":"45","author":"American Diabetes Association Professional Practice Committee","year":"2022","journal-title":"Diabetes Care"},{"key":"2026061619574906800_dgag056-B19"},{"issue":"6","key":"2026061619574906800_dgag056-B20","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1007\/s00198-014-2682-9","article-title":"The impact of common co-morbidities (as measured using the Charlson index) on hip fracture risk in elderly men: a population-based cohort study","volume":"25","author":"Reyes","year":"2014","journal-title":"Osteoporos Int"},{"issue":"5","key":"2026061619574906800_dgag056-B21","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"2026061619574906800_dgag056-B22","doi-asserted-by":"crossref","unstructured":"Kasher Meron, Hornik-Lurie, Twig, Rotman-Pikielny. Supplementary materials: GLP-1 receptor agonists and the risk of fragility fractures in older adults with type 2 diabetes. 10.5281\/zenodo.18404945. January 28, 2026.","DOI":"10.1210\/clinem\/dgag056"},{"issue":"10","key":"2026061619574906800_dgag056-B23","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1007\/s00198-017-4171-4","article-title":"Adverse bone effects of medications used to treat non-skeletal disorders","volume":"28","author":"Watts","year":"2017","journal-title":"Osteoporos Int"},{"key":"2026061619574906800_dgag056-B24","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2147\/CLEP.S444447","article-title":"Validity of major osteoporotic fracture diagnoses in the Danish national patient registry","volume":"16","author":"Clausen","year":"2024","journal-title":"Clin Epidemiol"},{"issue":"5","key":"2026061619574906800_dgag056-B25","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.reuma.2017.10.013","article-title":"Validation of fragility fractures in primary care electronic medical records: a population-based study","volume":"15","author":"Martinez-Laguna","year":"2019","journal-title":"Reumatol Clin (Engl Ed)"},{"issue":"27","key":"2026061619574906800_dgag056-B26","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1002\/sim.7501","article-title":"Practical recommendations for reporting Fine-Gray model analyses for competing risk data","volume":"36","author":"Austin","year":"2017","journal-title":"Stat Med"},{"key":"2026061619574906800_dgag056-B27","doi-asserted-by":"crossref","DOI":"10.1002\/9780470316696","volume-title":"Multiple Imputation for Nonresponse in Surveys","author":"Rubin","year":"1987"},{"issue":"8","key":"2026061619574906800_dgag056-B28","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/j.jclinepi.2013.01.013","article-title":"Prognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research","volume":"66","author":"Stuart","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"2026061619574906800_dgag056-B29","doi-asserted-by":"crossref","first-page":"117338","DOI":"10.1016\/j.bone.2024.117338","article-title":"Association of glucagon-like peptide-1 receptor agonists use with fracture risk in type 2 diabetes: a meta-analysis of randomized controlled trials","volume":"192","author":"Zhang","year":"2025","journal-title":"Bone"},{"key":"2026061619574906800_dgag056-B30","doi-asserted-by":"crossref","first-page":"882998","DOI":"10.3389\/fendo.2022.882998","article-title":"The risk of major osteoporotic fractures with GLP-1 receptor agonists when compared to DPP-4 inhibitors: a Danish nationwide cohort study","volume":"13","author":"Al-Mashhadi","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026061619574906800_dgag056-B31","doi-asserted-by":"crossref","first-page":"k4365","DOI":"10.1136\/bmj.k4365","article-title":"Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study","volume":"363","author":"Ueda","year":"2018","journal-title":"BMJ"},{"issue":"3","key":"2026061619574906800_dgag056-B32","doi-asserted-by":"crossref","first-page":"155","DOI":"10.7326\/M18-0567","article-title":"Fracture risk after initiation of use of canagliflozin: a cohort study","volume":"170","author":"Fralick","year":"2019","journal-title":"Ann Intern Med"},{"issue":"2","key":"2026061619574906800_dgag056-B33","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s00223-015-9993-5","article-title":"Bone fracture risk is not associated with the use of glucagon-like peptide-1 receptor agonists: a population-based cohort analysis","volume":"97","author":"Driessen","year":"2015","journal-title":"Calcif Tissue Int"},{"issue":"7","key":"2026061619574906800_dgag056-B34","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s00592-024-02415-w","article-title":"Fracture events associated with GLP-1 receptor agonists in FDA adverse events reporting system","volume":"62","author":"Xiao","year":"2025","journal-title":"Acta Diabetol"},{"issue":"10","key":"2026061619574906800_dgag056-B35","doi-asserted-by":"crossref","first-page":"e2130762","DOI":"10.1001\/jamanetworkopen.2021.30762","article-title":"Association of sodium-glucose cotransporter-2 inhibitors with fracture risk in older adults with type 2 diabetes","volume":"4","author":"Zhuo","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"5","key":"2026061619574906800_dgag056-B36","doi-asserted-by":"crossref","first-page":"e004431","DOI":"10.1136\/bmjdrc-2024-004431","article-title":"Recent trends in GLP-1 RA and SGLT2i use among people with type 2 diabetes and atherosclerotic cardiovascular disease in the USA","volume":"12","author":"King","year":"2024","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"1","key":"2026061619574906800_dgag056-B37","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1038\/s41598-017-03748-z","article-title":"Insulin use and excess fracture risk in patients with type 2 diabetes: a propensity-matched cohort analysis","volume":"7","author":"Losada-Grande","year":"2017","journal-title":"Sci Rep"},{"issue":"3","key":"2026061619574906800_dgag056-B38","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/oby.24222","article-title":"Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial","volume":"33","author":"Kushner","year":"2025","journal-title":"Obesity (Silver Spring, Md)"},{"issue":"19","key":"2026061619574906800_dgag056-B39","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"12","key":"2026061619574906800_dgag056-B40","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1002\/jbmr.2564","article-title":"Does diet-induced weight loss lead to bone loss in overweight or obese adults? A systematic review and meta-analysis of clinical trials","volume":"30","author":"Zibellini","year":"2015","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2026061619574906800_dgag056-B41","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/obr.12665","article-title":"A meta-analysis of the effects of bariatric surgery on fracture risk","volume":"19","author":"Zhang","year":"2018","journal-title":"Obes Rev"},{"issue":"1","key":"2026061619574906800_dgag056-B42","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41413-022-00190-4","article-title":"Mechanical regulation of bone remodeling","volume":"10","author":"Wang","year":"2022","journal-title":"Bone Res"},{"issue":"9","key":"2026061619574906800_dgag056-B43","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/dom.12932","article-title":"Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity","volume":"19","author":"Blundell","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"2026061619574906800_dgag056-B44","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1111\/dom.15802","article-title":"Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: a randomized controlled trial","volume":"26","author":"Gabe","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"2026061619574906800_dgag056-B45","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.2337\/dci24-0003","article-title":"Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity","volume":"47","author":"Drucker","year":"2024","journal-title":"Diabetes Care"},{"issue":"1","key":"2026061619574906800_dgag056-B46","doi-asserted-by":"crossref","first-page":"9151","DOI":"10.1038\/srep09151","article-title":"The relationship between dietary protein consumption and risk of fracture: a subgroup and dose-response meta-analysis of prospective cohort studies","volume":"5","author":"Wu","year":"2015","journal-title":"Sci Rep"},{"key":"2026061619574906800_dgag056-B47","doi-asserted-by":"crossref","first-page":"d1473","DOI":"10.1136\/bmj.d1473","article-title":"Dietary calcium intake and risk of fracture and osteoporosis: prospective longitudinal cohort study","volume":"342","author":"Warensj\u00f6","year":"2011","journal-title":"BMJ"},{"issue":"6","key":"2026061619574906800_dgag056-B48","doi-asserted-by":"crossref","first-page":"e2416775","DOI":"10.1001\/jamanetworkopen.2024.16775","article-title":"Bone health after exercise alone, GLP-1 receptor agonist treatment, or combination treatment: a secondary analysis of a randomized clinical trial","volume":"7","author":"Jensen","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"3","key":"2026061619574906800_dgag056-B49","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/jcsm.12411","article-title":"Sarcopenia and its association with falls and fractures in older adults: a systematic review and meta-analysis","volume":"10","author":"Yeung","year":"2019","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"2","key":"2026061619574906800_dgag056-B50","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.yexcr.2017.09.018","article-title":"Liraglutide, a glucagon-like peptide-1 receptor agonist, facilitates osteogenic proliferation and differentiation in MC3T3-E1 cells through phosphoinositide 3-kinase (PI3K)\/protein kinase B (AKT), extracellular signal-related kinase (ERK)1\/2, and cAMP\/protein kinase A (PKA) signaling pathways involving \u03b2-catenin","volume":"360","author":"Wu","year":"2017","journal-title":"Exp Cell Res"},{"key":"2026061619574906800_dgag056-B51","doi-asserted-by":"crossref","first-page":"110523","DOI":"10.1016\/j.biopha.2020.110523","article-title":"Liraglutide, a glucagon-like peptide-1 receptor agonist, suppresses osteoclastogenesis through the inhibition of NF-\u03baB and MAPK pathways via GLP-1R","volume":"130","author":"Li","year":"2020","journal-title":"Biomed Pharmacother"},{"issue":"11","key":"2026061619574906800_dgag056-B52","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1007\/s00198-025-07664-1","article-title":"Effects of glucagon-like peptide-1 receptor agonists on bone health in people living with obesity","volume":"36","author":"Karam","year":"2025","journal-title":"Osteoporos Int"},{"issue":"5","key":"2026061619574906800_dgag056-B53","doi-asserted-by":"crossref","first-page":"618","DOI":"10.7326\/M23-1490","article-title":"Newer pharmacologic treatments in adults with type 2 diabetes: a systematic review and network meta-analysis for the American college of physicians","volume":"177","author":"Drake","year":"2024","journal-title":"Ann Intern Med"},{"issue":"2","key":"2026061619574906800_dgag056-B54","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1210\/jc.2012-3118","article-title":"TBS (trabecular bone score) and diabetes-related fracture risk","volume":"98","author":"Leslie","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2026061619574906800_dgag056-B55","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.2337\/dc22-1253","article-title":"Pharmacologic treatment of type 2 diabetes in the U.S., Sweden, and Israel","volume":"45","author":"Lyu","year":"2022","journal-title":"Diabetes care"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag056\/66844317\/dgag056.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/7\/1949\/66844317\/dgag056.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/7\/1949\/66844317\/dgag056.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:57:57Z","timestamp":1781654277000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/111\/7\/1949\/8471581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":55,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,2,10]]},"published-print":{"date-parts":[[2026,6,17]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgag056","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,2,10]]}}}